With best-selling medicines for type 2 diabetes and obesity in hand, Novo Nordisk (NVO 2.37%) isn't content to let the chips fall where they may when it comes to patients having access to Ozempic and Wegovy. Thanks to the two drugs becoming a social phenomenon in the developed world, demand is running far above the company's ability to supply doses, potentially crimping its pace of revenue growth.But where there's a shortage, there's money to be made in closing the gap, and that's exactly what Novo Nordisk ...

Danish pharmaceutical company Novo Nordisk (NVO 2.37%) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for deploying capital in a mission-driven, efficient way to help broaden Novo Nordisk's reach.Earlier this week, Novo Holdings announced it was acquiring Catalent for a total enterprise value of $16.5 billion. Let's break down the deal and analyze why this transaction could be a game changer for Novo Nordisk in the lo ...

At the start of 2020, Novo Nordisk (NVO 0.89%) was worth around $150 billion. Today, its market capitalization is north of $500 billion as it is now one of the most valuable healthcare companies in the world.A big part of that reason is the rising popularity of two drugs: Ozempic and Wegovy. Both have been associated with helping patients shed significant amounts of weight. Thanks to social media, demand for the treatments has been through the roof, and that has sent the stock to new heights.But just how de ...

A major acquisition by its controlling shareholder pushed Novo Nordisk's (NVO 4.01%) U.S.-listed shares 4% higher on Monday. As a result of the deal, Novo Nordisk will acquire from that shareholder (Novo Holdings) three fill-finish sites currently operated by the acquisition target. The jump in Novo Nordisk's share price contrasted quite positively with the S&P 500 index's 0.3% slump for the session.Parent company buying Catalent in a deal worth $16.5 billionOn Monday morning, Novo Holdings revealed that it ...

Novo Nordisk (NVO) announced that it will acquire three manufacturing sites from Novo Holdings A/S for an upfront payment of $11 billion to expand its manufacturing capacity for obesity treatments.The announcement comes pursuant to Novo Holdings’ agreement to acquire global contract development and manufacturing organization Catalent, Inc. (CTLT) for $63.50 per share in cash.Novo Nordisk expects the acquisition to increase its filling capacity from 2026 onward. The three manufacturing sites (out of Catalent ...

Two of the most talked-about drugs in the U.S., obesity treatment Wegovy and diabetes medication Ozempic, are made by the same company: Denmark-based Novo Nordisk (NVO -1.80%). There wouldn't be so much chatter if these drugs weren't flying off pharmacy shelves these days, particularly in the case of Wegovy.Solid evidence of this was provided early this week by the company, which released highly encouraging quarterly and annual results featuring plenty of high-growth figures. Let's pick these apart a little ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks w ...

Novo Nordisk (NYSE:NVO) remains a buy for US bank Citigroup even though it is only the second European company in history to pass the half-a-trillion mark after LVMH temporarily hit the landmark last year. The Danish pharma accompanied its annual report with a management call that reiterated scaling up production of its blockbuster diabetes drugs Wegovy and Ozempic remains its number one priority. Capex will almost double to Dkr45bn in 2024 (15-17% of sales) with Novo expecting to post up to 25% revenue gro ...

For the first time since May, Novo Nordisk is gradually increasing the supply of its highly sought-after weight loss drug Wegovy. The Danish drugmaker told FOX Business the company is making significant investments in Wegovy, which gained significant attention since 2022 after being touted by high-profile figures and social media users for its weight loss effects. It "has been steadily increasing capacity to produce more Wegovy than ever before," the company said.  NOVO NORDISK'S WEGOVY REDUCES RISK OF SERI ...

Financial Data and Key Metrics Changes - In 2023, the company achieved a sales growth of 36% and an operating profit growth of 44%, both measured at constant exchange rates [7][22] - The gross margin increased to 84.6% compared to 83.9% in 2022, driven by a positive product mix [22] - Net profit increased by 51%, and diluted earnings per share rose by 52% to DKK 18.62 [25] Business Line Data and Key Metrics Changes - GLP-1 sales in diabetes increased by 52%, with North America growing by 52% and international operations by 53% [8] - Obesity care sales grew by 154%, with North America operations seeing a 212% increase [9] - Insulin sales decreased by 6%, primarily due to declining sales in the U.S. and China [8] Market Data and Key Metrics Changes - In North America, the company holds around 54% market share in the GLP-1 class [11] - The global diabetes value market share increased to 33.8%, surpassing the strategic aspiration of one-third [9] - In international operations, total diabetes care sales increased by 20%, driven by GLP-1 sales growing 53% [10] Company Strategy and Development Direction - The company aims to treat more patients with innovative treatments and has expanded its pipeline across all therapy areas [6] - A focus on sustainability is evident, with a 34% reduction in carbon emissions compared to pre-pandemic levels [5] - The company plans to increase capital expenditure to around DKK 45 billion in 2024 to expand production capacity [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued sales growth between 18% and 26% at constant exchange rates for 2024 [28] - The outlook reflects expectations for ongoing volume growth of GLP-1 treatments, despite potential supply constraints [29] - Management highlighted the importance of scaling supply to meet increasing demand, particularly with the launch of Wegovy [39] Other Important Information - The company returned over DKK 61.7 billion to shareholders through share buybacks and dividends in 2023 [27] - The company has proposed a final dividend of DKK 6.40 for 2023, marking a 50% increase compared to 2022 [27] Q&A Session Questions and Answers Question: Update on GLP-1/GIP dual agonist and oral amycretin - Management expressed confidence in managing GI toxicity during the titration phase for the once-monthly GLP-1/GIP [34] - No specific Phase 1 data for oral amycretin was disclosed, but management indicated progress in development [35] Question: Scaling supply and 340B policy revenue recognition - Management confirmed that scaling supply remains a priority and emphasized the importance of not annualizing Q4 results [38] - The company is only partially recognizing 340B revenue due to accounting standards, with ongoing litigation affecting future recognition [40] Question: Launch of Lilly Zepbound and NASH/MASH studies - Management indicated that market demand, competition, and supply capacity are considered in guidance [42] - The ESSENCE NASH study results are expected around the turn of the year, with further updates on the FGF21 study later [45] Question: Changes in competitive dynamics for Ozempic and Wegovy - Management noted stable formulary access for GLP-1s, with over 90% unrestricted access [66] - Stay time for Wegovy is reportedly better than previous treatments, with strong retention observed [67] Question: Guidance range for revenue growth and commercial coverage - The guidance range for revenue growth is wider due to market dynamics and supply constraints [72] - The company continues to enjoy broad market access for Wegovy, covering around 50 million people living with obesity [75]